AzTrials
AzTrials

Acute Coronary SyndromeBACCNCT02355457

Biomarkers in Acute Cardiac Care

An observational study of Acute Coronary Syndrome and Myocardial Infarction, run by Universitätsklinikum Hamburg-Eppendorf at 1 site in Germany.

Recruiting

Looking for participants now. Contact the study team or a site below to ask about taking part.

Sites and contacts
Official record
Search all trials

Trial summary

The primary aim of the study is to investigate new cardiac biomarkers and algorithms to diagnose acute coronary syndrome in patients with suspected acute myocardial infarction. Read more about this study

Who is it for?
Ages 18 years and older
How many people
5,000 participants
Where
1 siteGermany
Study dates
Jul 2013to Dec 2027
How long will I take part?
4 Years
Phase
Observational
Are there results?
Not yet: the study is under way

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 years and older
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Study population: All patients presenting with suspected myocardial infarction in the emergency department or the chest pain unit of the University Hospital Hamburg-Eppendorf.

Who may be able to join

  • Symptoms suggestive of acute myocardial infarction
  • Ability to provide written informed consent in accordance with Good epidemiological Practice and local legislation
  • Individuals at least 18 years old

Who cannot join

  • Insufficient knowledge of the German language (able to understand and write the German language)

Trial locations and contacts

1 site in 1 country. Contact the study team or a site near you to ask about taking part.

Johannes T Neumann, MD contact

0049407410 ext. 56800

j.neumann@uke.de

Nils Sörensen, MD contact

0049407410 ext. 56800

n.soerensen@uke.de

Germany1 site, 1 recruiting
  • Department of Cardiology, University Heart Center Hamburg

    Hamburg, 20246

    Johannes Neumann, MD, 0049407410 ext. 56800, j.neumann@uke.de

    Recruiting

Other trials in Germany

About this study

The primary aim of the study is to investigate new cardiac biomarkers and algorithms to diagnose acute coronary syndrome in patients with suspected acute myocardial infarction.

Read the detailed description

The primary aim of the study is to detect and evaluate new cardiac biomarkers, evaluate and improve acute coronary syndrome (ACS) risk scores, which takes into account clinical, gender specific, psycho-social and lifestyle-risk factors, protein patterns and genetic variability in addition to the classical risk factors with respect to the primary endpoint of acute myocardial infarction.

Secondary study aims are :

  • To provide estimates for the incidence of ACS in patients presenting with recent onset chest pain;
  • To provide accurate, quantifiable measures of precursors of ACS;
  • DNA, RNA, cells, and serum/plasma for comprehensive genetic, gene expression and proteomic studies
  • To explore the impact of ACS candidate genes on cardiovascular risk stratification by using genome-wide analyses and a biological systems approach;
  • To explore proteins relevant for ACS;
  • To allow the identification of new therapeutic targets;
  • To evaluate the impact of socio-economic factors on ACS and CAD risk.

Patients will be followed up during the hospital stay. Afterwards a telephone follow-up will take place after 30 days, 6, 24 and 48 months.

Keywords
troponin, myocardial infarction, acs, AMI, biomarker, BACC, high-sensitivity
Medical subject headings
Acute Coronary Syndrome, Myocardial Infarction, Chest Pain

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

Study groups in NCT02355457
Study groupRoleWhat they receive
Suspected acute myocardial infarctionPatients with recent onset symptoms suggesting acute myocardial infarction

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Acute myocardial infarction as index event

    The primary endpoint of the study is acute myocardial infarction

    Measured: Months

Secondary outcomes (1)
  1. AMI, Mortality, heart failure and quality of life

    The secondary endpoint of the study is mortality, heart failure, quality of life.

    Measured: Years

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted4 Feb 2015 (estimated)
  2. Study startJul 2013
  3. Primary completionDec 2027 (estimated)
  4. Study completionDec 2027 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Observational
Observational model
Cohort
Time perspective
Prospective
Enrolment
5,000 participants (estimated)
Target duration
4 Years
IDs, dates and publications
ClinicalTrials.gov ID
NCT02355457
Sponsor's protocol ID
PV4306
Acronym
BACC
Status last verified
May 2024
First submitted
30 Jan 2015
Last updated
13 May 2024
Results posted
No
Data monitoring committee
No
Individual data sharing
Undecided

Publications

  • Neumann JT, Sorensen NA, Schwemer T, Ojeda F, Bourry R, Sciacca V, Schaefer S, Waldeyer C, Sinning C, Renne T, Than M, Parsonage W, Wildi K, Makarova N, Schnabel RB, Landmesser U, Mueller C, Cullen L, Greenslade J, Zeller T, Blankenberg S, Karakas M, Westermann D. Diagnosis of Myocardial Infarction Using a High-Sensitivity Troponin I 1-Hour Algorithm. JAMA Cardiol. 2016 Jul 1;1(4):397-404. doi: 10.1001/jamacardio.2016.0695.

    PubMed 27438315
  • Neumann JT, Sorensen NA, Ojeda F, Schwemer T, Lehmacher J, Gonner S, Jarsetz N, Keller T, Schaefer S, Renne T, Landmesser U, Clemmensen P, Makarova N, Schnabel RB, Zeller T, Karakas M, Pickering JW, Than M, Parsonage W, Greenslade J, Cullen L, Westermann D, Blankenberg S. Immediate Rule-Out of Acute Myocardial Infarction Using Electrocardiogram and Baseline High-Sensitivity Troponin I. Clin Chem. 2017 Jan;63(1):394-402. doi: 10.1373/clinchem.2016.262659. Epub 2016 Nov 30.

    PubMed 27903616
  • Volschow B, Strauss B, Sorensen NA, Thiessen N, Lehmacher J, Toprak B, Abdennadher B, Dehkordi F, Haller PM, Scharlemann L, Schock A, Petersmann A, Gauss F, Twerenbold R, Neumann JT. Diagnostic validation of a novel high-sensitivity cardiac troponin T assay. Eur Heart J Acute Cardiovasc Care. 2026 Jul 8;15(7):535-544. doi: 10.1093/ehjacc/zuag044.

    PubMed 42008514
  • Glaeser J, Lopez-Ayala P, Kellner C, Boeddinghaus J, Nestelberger T, Koechlin L, Sorensen NA, Haller PM, Bima P, Crisanti L, Spagnuolo CC, Strebel I, Hure G, Sieber S, Rubini Gimenez M, Wildi K, Wussler D, Miro O, Martin-Sanchez FJ, Keller DI, Christ M, Twerenbold R, Mahfoud F, Neumann J, Mueller C; APACE and BACC Investigators. Comparison of the European Society of Cardiology 0/1-Hour and High-Sensitivity Troponin in the Evaluation of Patients With Suspected Acute Coronary Syndrome 0/2-or-0/3-Hour Algorithms for Rapid Myocardial Infarction Diagnosis: A Prospective Multicenter Study. J Am Coll Cardiol. 2026 May 5;87(17):2261-2278. doi: 10.1016/j.jacc.2025.12.056. Epub 2026 Feb 18.

    PubMed 41706062
  • Haller PM, Schock A, Kellner C, Lehmacher J, Toprak B, Hartikainen TS, Kiss KM, Alhaou G, Peifer K, Twerenbold R, Zeller T, Westermann D, Neumann JT, Sorensen NA. Bedside echocardiography in patients with suspected acute myocardial infarction without ST elevation. Clin Res Cardiol. 2025 Aug 19. doi: 10.1007/s00392-025-02724-2. Online ahead of print.

    PubMed 40828180
  • Thiebetaen N, Pickering JW, Kellner C, Haller PM, Lehmacher J, Toprak B, Twerenbold R, Sorensen NA, Pemberton C, Troughton R, Richards AM, Sharif S, Worster A, Than M, Kavsak PA, Neumann JT. A Common Algorithm for Cardiac Troponin to Rule Out and Rule in Acute Myocardial Infarction. Can J Cardiol. 2025 Jul;41(7):1351-1360. doi: 10.1016/j.cjca.2025.02.029. Epub 2025 Feb 26.

    PubMed 40021054
  • Haller PM, Kellner C, Sorensen NA, Lehmacher J, Toprak B, Schock A, Hartikainen TS, Twerenbold R, Zeller T, Westermann D, Neumann JT. Long-term outcome of patients presenting with myocardial injury or myocardial infarction. Clin Res Cardiol. 2025 Jun;114(6):700-708. doi: 10.1007/s00392-023-02334-w. Epub 2023 Nov 20.

    PubMed 37982865
  • Haller PM, Sorensen NA, Hartikainen TS, Gossling A, Lehmacher J, Toprak B, Twerenbold R, Richter J, Banko T, Korschid S, Schmidt J, Keller T, Zeller T, Blankenberg S, Westermann D, Neumann JT. Rising and Falling High-Sensitivity Cardiac Troponin in Diagnostic Algorithms for Patients With Suspected Myocardial Infarction. J Am Heart Assoc. 2023 May 16;12(10):e027166. doi: 10.1161/JAHA.122.027166. Epub 2023 May 9.

    PubMed 37158171
  • Neumann JT, Twerenbold R, Ojeda F, Aldous SJ, Allen BR, Apple FS, Babel H, Christenson RH, Cullen L, Di Carluccio E, Doudesis D, Ekelund U, Giannitsis E, Greenslade J, Inoue K, Jernberg T, Kavsak P, Keller T, Lee KK, Lindahl B, Lorenz T, Mahler SA, Mills NL, Mokhtari A, Parsonage W, Pickering JW, Pemberton CJ, Reich C, Richards AM, Sandoval Y, Than MP, Toprak B, Troughton RW, Worster A, Zeller T, Ziegler A, Blankenberg S; ARTEMIS study group. Personalized diagnosis in suspected myocardial infarction. Clin Res Cardiol. 2023 Sep;112(9):1288-1301. doi: 10.1007/s00392-023-02206-3. Epub 2023 May 2.

    PubMed 37131096
  • von Haehling S, Muller-Hennessen M, Garfias-Veitl T, Gossling A, Neumann JT, Sorensen NA, Haller PM, Hartikainen T, Vollert JO, Mockel M, Blankenberg S, Westermann D, Giannitsis E. Role of Copeptin and hs-cTnT to Discriminate AHF from Uncomplicated NSTE-ACS with Baseline Elevated hs-cTnT-A Derivation and External Validation Study. Cells. 2023 Mar 31;12(7):1062. doi: 10.3390/cells12071062.

    PubMed 37048135
  • Lehmacher J, Neumann JT, Sorensen NA, Gossling A, Schmidt SE, Zeller T, Blankenberg S, Westermann D, Clemmensen PM. Diagnostic performance of a device for acoustic heart sound analysis in patients with suspected myocardial infarction. Open Heart. 2023 Mar;10(1):e002090. doi: 10.1136/openhrt-2022-002090.

    PubMed 36858602
  • Hartikainen TS, Gossling A, Sorensen NA, Lehmacher J, Neumann JT, Blankenberg S, Westermann D. Prognostic Implications of a Second Peak of High-Sensitivity Troponin T After Myocardial Infarction. Front Cardiovasc Med. 2022 Jan 31;8:780198. doi: 10.3389/fcvm.2021.780198. eCollection 2021.

    PubMed 35174220
  • Neumann JT, Weimann J, Sorensen NA, Hartikainen TS, Haller PM, Lehmacher J, Brocks C, Tenhaeff S, Karakas M, Renne T, Blankenberg S, Zeller T, Westermann D. A Biomarker Model to Distinguish Types of Myocardial Infarction and Injury. J Am Coll Cardiol. 2021 Aug 24;78(8):781-790. doi: 10.1016/j.jacc.2021.06.027.

    PubMed 34412811
  • Haller PM, Neumann JT, Sorensen NA, Hartikainen TS, Gossling A, Lehmacher J, Keller T, Zeller T, Blankenberg S, Westermann D. The association of anaemia and high-sensitivity cardiac troponin and its effect on diagnosing myocardial infarction. Eur Heart J Acute Cardiovasc Care. 2021 Dec 18;10(10):1187-1196. doi: 10.1093/ehjacc/zuab066.

    PubMed 34350455
  • Sorensen NA, Gossling A, Neumann JT, Hartikainen TS, Haller PM, Scharlemann L, Lehmacher J, Ziegler A, Blankenberg S, Zeller T, Nordholt G, Renne T, Westermann D. Diagnostic Validation of a High-Sensitivity Cardiac Troponin I Assay. Clin Chem. 2021 Sep 1;67(9):1230-1239. doi: 10.1093/clinchem/hvab070.

    PubMed 34254126

Questions about this trial

What is this clinical trial studying?

An observational study of Acute Coronary Syndrome and Myocardial Infarction, run by Universitätsklinikum Hamburg-Eppendorf at 1 site in Germany.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 3 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: looking for participants now, as of the sponsor's last update on 13 May 2024. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Germany. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

This study is still under way. Results are not available in the source record yet.

How can a doctor refer a patient or contact the research team?

Contact Johannes T Neumann, MD (0049407410 ext. 56800, j.neumann@uke.de), or a site near the patient. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Acute myocardial infarction as index event (time frame: Months). It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT02355457, which also lists 27 linked publications.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 13 May 2024.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in